Eli Lilly’s experimental Alzheimer’s drug slows progression of the disease
Eli Lilly and Co. presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD).